Research Grade Rilonacept (HF943036)

Name: Research Grade Rilonacept
Brand: abinScience
SKU: HF943036
Price: 320 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HF943036
Description	Rilonacept (HF943036) is a research-grade recombinant antibody targeting Interleukin-1 beta. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Functional assay, Research in vivo
Host species	Human
Isotype	Fusion - [IL1RAP (interleukin-1 receptor accessory protein) - IL1R1 (type 1 interleukin-1 receptor, interleukin 1 receptor, type I)]2 - IGHG1 Fc (Fragment constant)
Expression system	Mammalian cells
Target	Interleukin-1 beta, IL1B, Catabolin, IL1F2, IL-1 beta
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P01584
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	501081-76-1
Background	Interleukin-1 beta (IL1B/IL1F2) is a ~30 kDa protein. Potent pro-inflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells. Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6. IL1B is the therapeutic target of canakinumab (Ilaris). 1. Tominaga, K. et al. (2000) International immunology 12, 151-60. PMID: 10653850 2. Nakahara, H. et al. (2003) Arthritis and rheumatism 48, 1521-9. PMID: 12794819 3. LaRock, CN. et al. (2016) Science immunology 1. PMID: 28331908 4. Van Damme, J. et al. (1985) Nature 314, 266-8. PMID: 3920526 5. Tian, XX. et al. (2021) International endodontic journal 54, 916-925. PMID: 33377178 6. Xia, S. et al. (2021) Nature 593, 607-611. PMID: 33883744
Note	For research use only. Not suitable for clinical or therapeutic use.